and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Receive News & Ratings for BioMarin Pharmaceutical ...
Hosted on MSN26d
BioMarin to Report Q4 Earnings: Here's What to ExpectHowever, BioMarin’s top-line growth is expected to have been partially offset by lower Kuvan sales, which have been suffering from generic erosion. The Zacks Consensus Estimate and our model est ...
In addition, BioMarin is well positioned to treat patients with phenylketonuria, or PKU, one of the world's most common metabolic disorders. While generic versions of Kuvan (mild to moderate PKU ...
BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy ...
A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...
BioMarin Pharmaceutical BMRN reported fourth ... This was partially offset by lower Kuvan sales. Royalty and other revenues totaled $11.7 million, down 11% year over year. Voxzogo, approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback